Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureResearch graph
References from Donor-targeted anti–HLA-A2 antibody shows nanogram-level efficacy in a novel GVHD mouse model. Local targets link to admitted publications; unresolved targets remain external evidence.
Steroid refractory acute GVHD: the hope for a better tomorrow
10.1002/ajh.27592 · 2025 · External reference
Lessons learned from early closure of a clinical trial for steroid-refractory acute GVHD
10.1038/s41409-021-01529-x · 2022 · External reference
Novel developments in the prophylaxis and treatment of acute GVHD
10.1182/blood.2023020073 · 2023 · External reference
Acute graft-versus-host disease
10.1038/s41572-023-00438-1 · 2023 · External reference
Graft-versus-host disease following liver transplantation: a systematic review of literature
10.1097/hc9.0000000000000260 · 2023 · External reference
How I diagnose and treat acute graft-versus-host disease after solid organ transplantation
10.1182/blood.2022015954 · 2023 · External reference
Selective depletion of naive T cells by targeting CD45RA
10.3389/fonc.2022.1009143 · 2022 · External reference
Post-transplant cyclophosphamide–based graft-versus-host disease prophylaxis attenuates disparity in outcomes between use of matched or mismatched unrelated donors
10.1200/jco.24.00184 · 2024 · External reference
A single dose of a CD137 antibody-drug conjugate protects rhesus macaque allogeneic HCT recipients against acute GVHD
10.1182/blood.2024027239 · 2025 · External reference
Effective treatment against severe graft-versus-host disease with allele-specific anti-HLA monoclonal antibody in a humanized mouse model
10.1016/j.exphem.2014.10.008 · 2015 · External reference
Donor-targeted serotherapy as a rescue therapy for steroid-resistant acute GVHD after HLA-mismatched kidney transplantation
10.1111/ajt.15827 · 2020 · External reference
A rapid and efficient strategy to generate allele-specific anti-HLA monoclonal antibodies
10.1016/j.jim.2009.01.007 · 2009 · External reference
Structural basis for the differential classification of HLA-A6802 and HLA-A6801 into the A2 and A3 supertypes
10.1016/j.molimm.2013.03.015 · 2013 · External reference
Engagement of MHC class I by the inhibitory receptor LILRB1 suppresses macrophages and is a target of cancer immunotherapy
10.1038/s41590-017-0004-z · 2018 · External reference
Xenogeneic graft-versus-host disease in NOD-scid IL-2Rγnull mice displays a T-effector memory phenotype
10.1371/journal.pone.0044219 · 2012 · External reference
Cytotoxic T-cell responses in HLA-A2.1 transgenic mice: recognition of HLA alloantigens and utilization of HLA-A2.1 as a restriction element
10.4049/jimmunol.142.4.1366 · 1989 · External reference
HLA and proteasome expression body map
10.1186/s12920-018-0354-x · 2018 · External reference
IFN-α activates dormant haematopoietic stem cells in vivo
10.1038/nature07815 · 2009 · External reference
Targeting leukemia stem cells in the bone marrow niche
10.3390/biomedicines6010022 · 2018 · External reference
Analysis of the frequencies of HLA-A, B, and C alleles and haplotypes in the five major ethnic groups of the United States reveals high levels of diversity in these loci and contrasting distribution patterns in these populations
10.1016/s0198-8859(01)00298-1 · 2001 · External reference
Six-locus high-resolution HLA haplotype frequencies derived from mixed-resolution DNA typing for the entire US donor registry
10.1016/j.humimm.2013.06.025 · 2013 · External reference
